Support CEPI

Join our coalition and help us create a future in which epidemics are no longer a threat to humanity.

Invest now

Why invest in CEPI

CEPI is a modern approach to an age-old problem—how to fund and develop vaccines to help prevent epidemics. CEPI offers a unique opportunity for our investors to lead on global health security and, in partnership with other governments and international organisations, invest in a solution that protects some of the most vulnerable people in the world while helping prevent the global spread of epidemics.

10 million

Lives were saved between 2010 and 2015 thanks to vaccines. (WHO, 2017)

$53 billion

The cost of the 2014 Ebola epidemic in west Africa. (C Huber et al, 2018)

$570 billion

The estimated annual global cost of moderately severe to severe pandemics (World Bank, 2017)

$2.8 billion

The average minimum cost for progressing one vaccine against each of WHO’s 11 priority epidemic infectious diseases. (D Gouglas et al, 2018)

Progress

Growing support from donors

CEPI was founded in Davos by the governments of Norway and India, the Bill & Melinda Gates Foundation, the Wellcome Trust, and the World Economic Forum.

To date, CEPI has secured over $760 million toward its $1 billion funding target, with financial support provided by the Bill & Melinda Gates Foundation, the Wellcome Trust, the European Commission, and the governments of Australia, Belgium, Canada, Ethiopia, Germany, Japan, Norway and the UK.

Calls for Proposals successfully announced

Since our launch in 2017, CEPI has announced a number of calls for funding proposals. The first call supports candidate vaccines against Middle East Respiratory Syndrome coronavirus (MERS-CoV), Nipah virus, and Lassa virus. The second call will advance rapid response vaccine platforms against unknown pathogens, known as 'Disease X'. The third call is supporting vaccines against Rift Valley fever and Chikungunya viruses. We also launched a call in October 2019, is for the development of innovative platform technologies that can be used to develop vaccines and other immunoprophylactics to rapidly respond to future outbreaks of emerging infectious diseases and “Disease X”.

Most recently, we ran a funding call to develop and manufacture already proven vaccine technology that can be used against virus behind COVID-19.

Partnership agreements launched

To date, CEPI has committed to investing up to $475 million in vaccine development. This includes 19 vaccine candidates against its priority pathogens (six against Lassa virus, five against MERS-CoV, four against Nipah virus, two against Chikungunya, two against Rift Valley fever) and three vaccine platforms to develop vaccines against Disease X. To assess the effectiveness of these platforms 7 additional vaccine candidates are being developed (two against influenza, one against Marburg virus, two against Rabies virus, one against Respiratory Syncytial Virus, and one against yellow fever).

Our vaccine development partners include Emergent Biosolutions, Janssen Vaccines & Prevention B.V., Imperial College London, CureVac, IDT Biologika, Inovio, the International AIDS Vaccine Initiative (IAVI), Profectus Biosciences, Themis Bioscience, Public Health Vaccines, Valneva SE, Colorado State University, PATH, Wageningen Bioveterinary Research, University of Tokyo, University of Queensland, and University of Oxford.

In addition, CEPI has announced funding for four programmes with Inovio, University of Queensland, Moderna, and Curevac, to rapidly advance the development of vaccine candidates against 2019-nCoV. GSK has also announced that it will make its established pandemic vaccine adjuvant platform technology available to enhance the development of an effective vaccine against the virus behind the disease COVID-19.

Ebola and Zika showed that the world is tragically unprepared to detect local outbreaks and respond quickly enough to prevent them from becoming global pandemics. Without investments in research and development, we will remain unequipped when we face the next threat.

The ability to rapidly develop and deliver vaccines when new ‘unknown’ diseases emerge offers our best hope to outpace outbreaks, save lives and avert disastrous economic consequences. CEPI is a great example of how supporting innovation and R&D can help the world to address some of its most pressing health challenges.

Bill Gates, Co-Chair

Bill and Melinda Gates Foundation

Just over a year ago 193 states adopted the Sustainable Development Goals – the roadmap for the future we want. Epidemics threaten that future. They can ruin societies on a scale only matched by wars and natural disasters. They respect no borders and don’t care if we are rich or poor. Protecting the vulnerable is protecting ourselves. This is why we all must work together to be better prepared – and why my Government is fully committed to ensure that CEPI achieves its mission.

Erna Solberg, Prime Minister

Government of Norway

Japan has highlighted the importance of pandemic preparedness and Universal Health Coverage. I believe the CEPI will contribute to achieving them through encouraging development of vaccines.

Yasuhisa Shiozaki, Minister of Health, Labour, and Welfare

Government of Japan

The outbreak of diseases like MERS, Ebola, or Lassa fever will continue to pose a threat to many people’s health as long as there are no effective vaccines. This is why we are involved in the CEPI initiative, whose objective is to prevent future epidemics by developing novel vaccines.

Anja Karliczek, Federal Minister of Education and Research

Government of Germany

We know from Ebola, Zika and SARS that epidemics are among the significant threats we face to life, health and prosperity. Vaccines can protect us, but we’ve done too little to develop them as an insurance policy. CEPI is our chance to learn the lessons of recent tragedies, and outsmart epidemics with new vaccine defences. If others join us in supporting CEPI, we can realise our goal of creating a safer world

Dr Jeremy Farrar, Director

The Wellcome Trust

Recent epidemics taught the world the hard way that infectious diseases know no borders. The EU shares the CEPI objective to develop new vaccines that will help prevent and contain future epidemics, and is committed to collaborating with CEPI in joint efforts towards this goal.

Carlos Moedas, EU Commissioner for Research, Science and Innovation

European Commission

The Australian Government is invested in the global effort to fund critical research and development gaps for pandemic preparedness and global health security. Australia is committed to global health, and will continue to build global innovative partnerships and seek out opportunities for international research collaboration. Australia’s contribution to the Coalition of Epidemic Preparedness Innovations, through the Medical Research Future Fund, will assist in the development of vital vaccines suitable for humans that are deploy-ready before an epidemic begins, and ensure we are prepared for future epidemics.

Government of Australia

Invest now

Work with CEPI

Funding opportunities

We create innovative partnerships between public, private, philanthropic, and civil organisations to develop vaccines against diseases with epidemic potential.

We invest in promising vaccine candidates against our priority pathogens and platform technologies that can enable rapid development of vaccines and immunoprophylactics against new and unknown pathogens. We also coordinate activities to improve our collective response to epidemics.

Learn more about our funding opportunities.

CALLS FOR PROPOSALS

We are supporting all areas of vaccine science.

CEPI aims to invest in vaccine-based solutions that not only protect some of the most vulnerable people in the world but will also help to prevent future pandemics.

Get in touch to find out how your organisation could work with CEPI.